What Is The Minimum costs to produce Hepatitis C Direct Acting Antivirals
Zlikster said
Nov 13, 2013
this should be a sticky thread...this information should be available to public, just to comprehend the scale of money being involved, patents exp dates, etc...
Tig said
Nov 13, 2013
WOW is right! Just leaves me without adequate words to share. It's obvious that if Big Pharm wanted to make these treatments available to everyone that needed it, they could provide it at an affordable price to everyone and still make the fortune that holds so much importance to them. Apparently "enough" is never enough for some...
Matt Chris said
Nov 13, 2013
Hey Karen
Wow! read through the PDF who ever compiled this data did a ton of work. I did not realize China has 30 million, India has nearly 20 million people infected with Hep. With the raw cost of these new DAA's being less that $1,000.00 for a treatment course and Big Pharma's charge to the customer being higher that $50,000 per treatment it's highly likely IMO that India or China will ignore the Patent and manufacture a version of these new DAA's sometime in the future or cut a licensing deal with one of these countries. Perhaps this will be Gilead's pay back for slowing down the cure of HCV.
matt
Zlikster said
Nov 13, 2013
wow. now i get it. PegIntron price over here and Roche's agressive advertising for Pegasys, few more years and patent is no more. Thats why one infektologists doc said to me Ribavirin is almost free/subsidized. As for production cost of DAAs, i am not surprised. So production cost (in my case) for Sofosbuvir 24w could be 300$....speachless. If the price for 24w, 180 pills of Sof will be 120k $, do the math. I do not want to rant anymore ;/
thanks Karen!
Loopy Lisa said
Nov 13, 2013
Thanks for posting, very interesting data. Let's see what they actually charge us for the new treatments!
this should be a sticky thread...this information should be available to public, just to comprehend the scale of money being involved, patents exp dates, etc...
WOW is right! Just leaves me without adequate words to share. It's obvious that if Big Pharm wanted to make these treatments available to everyone that needed it, they could provide it at an affordable price to everyone and still make the fortune that holds so much importance to them. Apparently "enough" is never enough for some...
Hey Karen
Wow! read through the PDF who ever compiled this data did a ton of work. I did not realize China has 30 million, India has nearly 20 million people infected with Hep. With the raw cost of these new DAA's being less that $1,000.00 for a treatment course and Big Pharma's charge to the customer being higher that $50,000 per treatment it's highly likely IMO that India or China will ignore the Patent and manufacture a version of these new DAA's sometime in the future or cut a licensing deal with one of these countries. Perhaps this will be Gilead's pay back for slowing down the cure of HCV.
matt
thanks Karen!
Thanks for posting, very interesting data. Let's see what they actually charge us for the new treatments!
Interesting data...
http://hepatitiscnewdrugs.blogspot.co.uk/2013/11/aasld-sofosbuvirsimeprevir-what-is.html
-- Edited by Karen on Wednesday 13th of November 2013 02:07:00 PM